Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.06 USD

806.06
3,599,482

-0.08 (-0.01%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $804.12 -1.94 (-0.24%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

New Strong Sell Stocks for May 19th

ALBO, BFIN, GOOS, DKNG, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2021

Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC

Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.

New Strong Sell Stocks for May 13th

PRTS, CIGI, ELMD, LLY, and TTWO have been added to the Zacks Rank #5 (Strong Sell) List on May 13, 2021

Biohaven (BHVN) Q1 Earnings Miss, Nurtec Uptake Remains Strong

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.

New Strong Sell Stocks for May 11th

PFPT, KLR, GDDY, LLY, and FUV have been added to the Zacks Rank #5 (Strong Sell) List on May 11, 2021

Radius (RDUS) Q1 Loss Narrower than Expected, Revenues Lag

Radius (RDUS) reports a narrower loss but misses on sales in the first quarter as lead drug sales decline.

United Therapeutics (UTHR) Q1 Earnings Miss, Sales Beat

United Therapeutics (UTHR) reports mixed first-quarter 2021 results. Higher sales of Orenitram, Unituxin and Tyvaso offset lower sales of Remodulin and Adcirca.

Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) beat estimates for both earnings and sales in the first quarter of 2021.

Incyte (INCY) Q1 Earnings Beat, Sales Miss on Soft Jakafi

Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.

Kinjel Shah headshot

3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes

Most Large Cap Pharmaceuticals industry players' Q1 results have been disappointing. Launch of COVID-19 vaccines and medicines is playing a crucial role in driving the industry. PFE, JNJ and AZN may prove to be good additions to your portfolio.

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, GlaxoSmithKline, Novartis and Johnson & Johnson

Kinjel Shah headshot

Pharma Stock Roundup: Big Drugmakers' Q1 Earnings, Resumption of JNJ US COVID-19 Jabs

Several large drugmakers announce Q1 earnings. Many miss estimates for both earnings and sales. J&J (JNJ) resumes COVID-19 vaccination in the United States.

Company News for Apr 28, 2021

Companies in The News Are: LLY,ADM,UPS,CNC

Mark Vickery headshot

Markets, GE Q1 Mixed; UPS Beats Big

United Parcel Service (UPS) put up a legitimate blowout quarter for Q121, far surpassing expectations in the Zacks consensus.

Earnings Season in Full Swing

Earnings Season in Full Swing

Eli Lilly (LLY) Q1 Earnings Miss, COVID-19 Drug Demand Low

Lilly (LLY) misses first-quarter estimates for both earnings and sales. It narrows 2021 forecast. Stock down in pre-market trading.

Eli Lilly (LLY) Q1 Earnings and Revenues Miss Estimates

Lilly (LLY) delivered earnings and revenue surprises of -11.79% and -1.23%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates

J&J (JNJ) beats Q1 estimates for earnings and sales. Roche (RHHBY) announces Q1 sales numbers.

Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

Style Box ETF report for FLQL

What's in the Cards for Eli Lilly (LLY) This Earnings Season?

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) first-quarter sales.

Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo

Lilly (LLY) plans to stop COVID-19 treatment with bamlanivimab alone in the United States. Instead, a combination of bamlanivimab and etesevimab will be available for the same, a better therapy for variants.

Merck (MRK) Stops MK-7110 Development, Focuses on Molnupiravir

Merck (MRK) will start evaluating oral molnupiravir in non-hospitalized COVID-19 patients in a late-stage study. It stops MK-7110 development due to requirement of additional studies.

Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU

The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's COVID-19 Vaccine Woes, MRK Ends COVID-19 Drug Development

FDA & CDC temporarily halt J&J's (JNJ) COVID-19 vaccine use. Merck (MRK) ends development of COVID-19 drug.